NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
biote Corp. BTMD
5 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$192.2M
▼ 2.5% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
6%
ROE · FY25
—
Net margin · FY25
14.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 192.2M
Revenue, FY2025 · full 5-year series below
Revenue
Net income
14 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin18.5%
Net margin14.1%
Return on assets23.5%
Returned to shareholders
USD 4.9M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.7M
Net buybacksUSD 3.1M
Share of profit18.0%
Consecutive raises—
USD 1.7M in dividends and USD 3.1M in buybacks — 18% of the year's profit went back to shareholders.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.2%
Returned to shareholders
−27.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 107.6M
total assets, end of FY2025
Total assetsUSD 107.6M
EquityUSD -58.5M
CashUSD 24.1M
Gross debtUSD 102.0M
Net debtUSD 77.9M
Current ratio1.22×
Net debt stands at -133% of equity.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
Revenue $B
0.2
0.2
0.2
0.2
0.1
Operating income $B
0.0
0.0
0.0
−0.1
0.0
EBITDA $B
0.0
0.0
0.0
−0.1
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.0
−0.0
0.0
EPS, diluted $
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
Payout %
6
150
262
−1330
35
ROE %
·
·
·
·
790.8
Shares out B
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
14 of 14
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed